Citadel Advisors’s General Moly, Inc. GMO Stock Holding History

Citadel Advisors’s Portfolio GMO Stock Details GMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,500	Closed	-$1K	–	9402
2015 Q2	$1K	Buy	+1,500	New	+$1.07K	﹤0.01%	8657
2014 Q3	–	Sell	-3,500	Closed	-$4K	–	8548
2014 Q2	$4K	Buy	+3,500	New	+$3.65K	﹤0.01%	7775
2013 Q4	–	Sell	-2,000	Closed	-$3K	–	7247
2013 Q3	$3K	Sell	2,000 -4,300	-68%	-$7.75K	﹤0.01%	6633
2013 Q2	$12K	Buy	+6,300	New	+$12.4K	﹤0.01%	6199

Other funds holding GMO

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

Citadel Advisors's GMO Position: Q4 2020 in Review

Citadel Advisors sold out of General Moly, Inc. (GMO) in Q4 2020, closing a stake of 30,421 shares — an estimated $3K sold.

Citadel Advisors first reported a position in GMO in Q2 2013 and held it in 22 quarters. The position peaked at $185K in Q2 2013. 7 funds tracked by Wall St. Rank hold GMO as of Q4 2020.

Citadel Advisors reported no remaining General Moly, Inc. position as of Q4 2020 after selling out during the quarter.
Citadel Advisors sold 30,421 General Moly, Inc. shares in Q4 2020, an estimated $3K.
Citadel Advisors first reported a position in General Moly, Inc. in Q2 2013 and held it in 22 quarters.
Citadel Advisors's General Moly, Inc. position peaked at $185K in Q2 2013.
7 funds tracked by Wall St. Rank held General Moly, Inc. as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.